Spots Global Cancer Trial Database for BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
Official Title: Phase I Dose Escalation Study to Determine the Safety, Pharmacokinetics and Pharmacodynamics of BMS-582664 in Combination With Full Dose Erbitux in Patients With Advanced Gastrointestinal Malignancies Who Have Failed Prior Therapy
Study ID: NCT00207051
Conditions
Interventions
Study Description
Brief Summary: This is a phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in combination with full dose erbitux in patients with advanced colorectal cancer who have received no more than 2 prior regimens for metastatic colorectal cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Georgetn Univ Lombardi Can Ctr, Washington, District of Columbia, United States
University Of Miami Miller School Of Medicine, Miami, Florida, United States
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Local Institution, Hamilton, Ontario, Canada
Local Institution, Toronto, Ontario, Canada
Local Institution, Amsterdam, , Netherlands
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
